Research Topics
| Renato BassanSummaryAffiliation: Ospedali Riuniti Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Renato Bassan
Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy
Blood 113:4153-62. 2009..001) using a level of 10(-4) or higher to define persistent disease. MRD analysis during early postremission therapy improves risk definitions and bolsters risk-oriented strategies. ClinicalTrials.gov identifier: NCT00358072...- Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00Renato Bassan
U S C Ematologia, Ospedali Riuniti, Bergamo, Italy
J Clin Oncol 28:3644-52. 2010.... - Modern therapy of acute lymphoblastic leukemiaRenato Bassan
Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
J Clin Oncol 29:532-43. 2011..These changes are improving long-term outcome, which in ongoing studies is expected close to 50% or greater... 
Evolving strategies for the management of high-risk adult acute lymphoblastic leukemiaRenato Bassan
Division of Hematology, Ospedali Riuniti, Bergamo, Italy
Haematologica 90:1299. 2005- Adult acute lymphoblastic leukaemiaRenato Bassan
Ospedali Riuniti, Bergamo, Italy
Crit Rev Oncol Hematol 50:223-61. 2004..Therapeutic progress may be obtainable through a careful integration of chemotherapy, stem cell transplantation, and the new targeted treatments with highly specific metabolic inhibitors and humanised monoclonal antibodies... - Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemiaOrietta Spinelli
Hematology and Bone Marrow Transplantation Units of Ospedali Riuniti Bergamo, Bergamo, Italy
Haematologica 92:612-8. 2007..The aim of this study was to correlate the kinetics of MRD clearance after allogeneic transplantation with the clinical outcome of adults with ALL... - Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphomaSergio Cortelazzo
Division of Hematology, Ospedale Civile, Bolzano, Italy
Ann Hematol 91:73-82. 2012.... - A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromesTamara Intermesoli
Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy
Br J Haematol 147:681-5. 2009..Low-dose, short-course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre-defined FIP1L1 rearrangement subset... - The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysisJosee Golay
Laboratory of Cellular and Gene Therapy G Lanzani, Division of Haematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
Haematologica 91:322-30. 2006..Campath-1H is used in conditioning regimens and more recently as an anti-leukemic therapy in acute lymphoblastic leukemias (ALL). We therefore investigated CD52 expression and campath-1H-mediated lysis of ALL cells in vitro... - Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groupsRenato Bassan
Division of Haematology, Cytogenetics Unit, Ospedali Riuniti, Bergamo, Italy
Hematol J 3:193-200. 2002..An exploratory trial was conducted to evaluate toxicity and potential therapeutic role of all trans-retinoic acid (ATRA) given long-term together with chemotherapy and G-CSF to adult patients with acute myelogenous leukemia (AML)... - Abnormally expanded pro-B hematogones associated with congenital cytomegalovirus infectionTamara Intermesoli
USC Ematologia, Ospedali Riuniti, Bergamo, Italy
Am J Hematol 82:934-6. 2007.... - Immunophenotypic evaluation of circulating T-cell clones in hypereosinophilic syndromes with or without abnormal CD3 and CD4 lymphocytesRenato Bassan
Division of Hematology, Ospedali Riuniti, Bergamo; Italy
Haematologica 89:238-9. 2004 - Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemiaRenato Bassan
Department of Hematology, Ospedali Riuniti, Largo Barozzi 1, 24100 Bergamo, Italy
Haematologica 87:257-63. 2002..The principal aim was to define the maximum tolerated dose (MTD) of IDR, which is reported to be a less MDR1-sensitive anthracycline. The short CsA infusion was patterned after the results of a previous in vitro study... - Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci
, University of Bologna, Bologna, Italy
Clin Cancer Res 12:3037-42. 2006..0005 and as a 3-log reduction from median baseline value) already at the time of first achieving a CCgR have significantly longer cytogenetic remission durations than those without this magnitude of molecular response (P < 0.05)... - Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patientsEros Di Bona
Department of Haematology, Vicenza Hospital, Vicenza, Italy
Leuk Lymphoma 46:879-84. 2005..In spite of 12 HSCTs, there was no long-term survivor. 'ABC' salvage proved feasible and comparable to reported rescue chemotherapic regimens, but the achievement of cure in refractory/relapsing ALL remains an outstanding clinical task... - Adult acute myeloid leukaemiaMatthew Smith
St Bartholomew's Hospital, London, UK
Crit Rev Oncol Hematol 50:197-222. 2004....